Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Below 200 Day Moving Average – Time to Sell?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.36 and traded as low as $2.36. Oramed Pharmaceuticals shares last traded at $2.37, with a volume of 43,141 shares traded.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded shares of Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 19th.

Oramed Pharmaceuticals Stock Down 2.1 %

The stock has a market capitalization of $94.73 million, a price-to-earnings ratio of 21.36 and a beta of 1.61. The company’s fifty day simple moving average is $2.30 and its 200 day simple moving average is $2.36.

Hedge Funds Weigh In On Oramed Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ORMP. BML Capital Management LLC grew its stake in shares of Oramed Pharmaceuticals by 20.9% in the fourth quarter. BML Capital Management LLC now owns 2,643,907 shares of the biotechnology company’s stock valued at $6,398,000 after acquiring an additional 457,716 shares in the last quarter. Peapod Lane Capital LLC acquired a new position in shares of Oramed Pharmaceuticals in the fourth quarter valued at about $550,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Oramed Pharmaceuticals in the third quarter valued at about $272,000. Dimensional Fund Advisors LP grew its stake in shares of Oramed Pharmaceuticals by 143.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 70,190 shares in the last quarter. Finally, Marquette Asset Management LLC acquired a new position in shares of Oramed Pharmaceuticals in the fourth quarter valued at about $81,000. 12.73% of the stock is currently owned by institutional investors and hedge funds.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.